Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.71 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.71 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.71 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | EDNRA | P25101 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | HTR2B | P41595 | 1/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.71 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.71 |
| ▸ | ACHE | P22303 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816946 | 0.92 | AGTR1 (0.67) | AGTR1LTB4R2AGTR2ABCC3ABCC4 | |
| SCHEMBL8199729 | 0.89 | AGTR1 (0.74) | AGTR1LTB4R2AGTR2ABCC3ABCC4 | |
| SCHEMBL10109133 | 0.84 | AGTR1 (0.67) | AGTR1LTB4R2AGTR2ABCC3ABCC4 | |
| SCHEMBL21083913 | 0.84 | AGTR1 (0.58) | AGTR1LTB4R2AGTR2ABCC3ABCC4 | |
| SCHEMBL21084024 | 0.83 | ACHE (0.58) | AGTR1LTB4R2AGTR2ABCC3ABCC4 | |
| SCHEMBL25144969 | 0.83 | AGTR1 (0.63) | AGTR1LTB4R2AGTR2ABCC3ABCC4 | |
| Irbesartan SCHEMBL285754 | 0.83 | AGTR1 (1.00) | AGTR1LTB4R2AGTR2ABCC3ABCC4 | |
| SCHEMBL25144962 | 0.83 | AGTR1 (0.65) | AGTR1LTB4R2AGTR2ABCC3ABCC4 | |
| SCHEMBL24360482 | 0.82 | ACHE (0.72) | AGTR1LTB4R2AGTR2ABCC3ABCC4 | |
| SCHEMBL2558334 | 0.82 | AGTR1 (0.69) | AGTR1LTB4R2AGTR2ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | AGTR1 2377/4885LTB4R2 1575/4885AGTR2 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.